The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
Open accessAbstract
Purpose: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer characterized by rearrangement of the NUT gene. Research advances have provided opportunities for targeted therapy in NMC, yet the clinical features of this rare disease have not been systematically characterized. We report on a large population of such patients to identify the disease characteristics and treatments, correlate them with outcome, and to consider clinical recommendations. Experimental Design: A clinical database was established using retrospective demographic and outcomes data available on all known cases of NMC. Questionnaires were completed by treating physicians. Pathologic, demographic, and clinical variables were assessed for 63 patients, the largest cohort of patients with NMC studied to date. Outcome data from 54 patients were available for survival analyses. Results: The diagnosis of NMC has increased annually since 2007. Since 2009, there has been an observed increase in the age at diagnosis (P < 0.05). Geographic distribution of patients with NMC has been concentrated in the United States (n = 41, 65%). The median overall survival for patients with NMC was 6.7 months. The 2-year progression-free survival (PFS) was 9% with a 95% confidence interval (CI) of 1% to 17% [1-year PFS 15% (5–24%) and 2-year overall survival (OS) was 19% with a 95% CI of 7%–31% (1-year OS: 30% (27–34%)]. Multivariate analysis suggested that extent of surgical resection and initial radiotherapy were independent predictors of PFS and OS. Notably, no chemotherapeutic regimen was associated with improved outcome. Conclusions: NMC portends a poor prognosis among all squamous cell neoplasms and seems to be frequently unrecognized. The finding that conventional chemotherapy has been inadequate indicates a pressing need for the development of targeted therapeutics. Intensive local therapies such as gross total resection and radiotherapy might be associated with enhanced survival. Clin Cancer Res; 18(20); 5773–9. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“Recently, our group developed first-in-class, direct-acting inhibitors of the BRD3 and BRD4 bromodomains, as targeted therapy for NMC (25).”
BackgroundSelf-citationBRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
Self-citationFrench, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441
Self-citationDiagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody
Haack, H., Johnson, L. A., Fry, C. J., Crosby, K., Polakiewicz, R. D., Stelow, E. B., Hong, S.-M., Schwartz, B. E., Cameron, M. J., Rubin, M. A., et al. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318198d666 · Cited by 435
Self-citationMidline Carcinoma of Children and Young Adults With NUT Rearrangement
French, C. A., Kutok, J. L., Faquin, W. C., Toretsky, J. A., Antonescu, C. R., Griffin, C. A., Nose, V., Vargas, S. O., Moschovi, M., Tzortzatou-Stathopoulou, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.107 · Cited by 410
Self-citationPathogenesis of NUT Midline Carcinoma
French, C. A. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132438 · Cited by 264
Self-citationDifferentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3513 · Cited by 217
Self-citationBRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19)
French, C. A., Miyoshi, I., Aster, J. C., Kubonishi, I., Kroll, T. G., Dal Cin, P., Vargas, S. O., Perez-Atayde, A. R., & Fletcher, J. A. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63049-0 · Cited by 206
Self-citationToretsky, J. A., Jenson, J., Sun, C. J., Eskenazi, A. E., Campbell, A., Hunger, S. P., Caires, A., Frantz, C. N., Hill, J. L., & Stamberg, J. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000020960.98562.84 · Cited by 67
Cited by
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx, A., Chan, J. K. C., Coindre, J.-M., Detterbeck, F., Girard, N., Harris, N. L., Jaffe, E. S., Kurrer, M. O., Marom, E. M., Moreira, A. L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000654 · Cited by 603
Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.-P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., & French, C. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1335 · Cited by 378
Self-citation
Metadata
- Authors
- Bauer, D. E., Mitchell, C. M., Strait, K. M., Lathan, C. S., Stelow, E. B., Lüer, S. C., Muhammed, S., Evans, A. G., Sholl, L. M., Rosai, J., Giraldi, E., Oakley, R. P., Rodriguez-Galindo, C., London, W. B., Sallan, S. E., Bradner, J. E., & French, C. A.
- Venue
- Clinical Cancer Research
- Published
- 2012-10-14
- Volume
- 18
- Issue
- 20
- Pages
- 5773-5779
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2144858115
- Cited by
- 412
- References
- 9
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-1153
- The paper
- Bauer, D. E., Mitchell, C. M., Strait, K. M., Lathan, C. S., Stelow, E. B., Lüer, S. C., Muhammed, S., Evans, A. G., Sholl, L. M., Rosai, J., Giraldi, E., Oakley, R. P., Rodriguez-Galindo, C., London, W. B., Sallan, S. E., Bradner, J. E., & French, C. A. (2012). Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-1153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.